Survivin

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024
Growth, Sale, Ovarian cancer, Protein, Intellectual property, CD8, B cell, Cyclophosphamide, BRCA, APC, Pet, Pfizer, CD4, FRA, Allergy, Vaccine, IMV, Peptide, Limited partnership, Antigen, Patent, Infection, DLBCL, Acquisition, Merck, Livestock, USD, Messenger, DSM-IV codes, Cancer, Platinum, Survivin, Patient, Medicine

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024
Growth, Sale, Ovarian cancer, Protein, Intellectual property, CD8, B cell, Cyclophosphamide, BRCA, APC, Pet, Pfizer, CD4, FRA, Allergy, Vaccine, IMV, Peptide, Limited partnership, Antigen, Patent, Infection, DLBCL, Acquisition, Merck, Livestock, USD, Messenger, DSM-IV codes, Cancer, Platinum, Survivin, Patient, Medicine

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, EU4, DNA, Bevacizumab, Malignancy, Radiation, Temozolomide, GBM, Survivin, Neoplasm, Epidemiology, Survival, Forest Law Enforcement and Governance Program, Cancer, Genentech, Immunotherapy, USD, Incidence, VEGF, Health insurance coverage in the United States, Congress of Neurological Surgeons, VBL, AANS, American Association of Neurological Surgeons, Patient, Patent, Ofranergene obadenovec, IDH1, Growth, Merck, FDA, Therapy, Disease, Mobile phone, Health care, Pharmaceutical industry, Glioma

The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Key Points: 
  • The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.
  • Epidemiology: Glioma's epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032.
  • The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent.
  • Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies.

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Retrieved on: 
Monday, June 26, 2023
Immortalised cell line, Marker, Antigen, DNA, PI, ARTEMIS, Survivin, SBIR, Majesty of the Seas, HMA, Clinical trial, NIH, Gene expression, Cell, HSCT, Bangladesh Technical Education Board, Oncogene, PRAME, Acute myeloid leukemia, THP-1 cell line, Trial of the century, AML, THP-1, Patient, Small Business Innovation Research, WT-1, Wong, DNA methylation, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DMSO, Food, Safety, Bone marrow, Pharmaceutical industry, Vaccine, Decitabine

MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.

Key Points: 
  • MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.
  • Given the promising responses in patients who are MRD+, Marker has been investigating clinical opportunities to further improve AML patient outcomes.
  • One such opportunity is to combine multiTAA-specific T cell therapy with agents that make cancer cells more visible to cancer killing cells.
  • These in vitro data demonstrate that administration of MT-401 following HMA infusion enhanced AML cell killing and could offer a new therapeutic option for AML patients post-HSCT.

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Retrieved on: 
Wednesday, May 31, 2023
Lymphoma, Baylor, Antigen, Marker, Probability, CD19, Vasileiou, Chong, TAA, Neoplasm, The New England Journal of Medicine, Drug discovery, Clinical trial, SSX2, PRAME, CAR, Patient, Standard of care, WT-1, Growth, FDA, Therapy, IND, Safety, Bone marrow, Vaccine, Pharmaceutical industry, Survivin, Research

The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.

Key Points: 
  • The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.
  • Prior to starting the clinical trial Marker assessed the killing capacity of MT-601 in vitro in a lymphoma cell line and demonstrated that MT-601 kills lymphoma cells regardless of their CD19 expression levels.
  • Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited growth of lymphoma cells as well as the growth of CD19 CAR resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics.
  • While the CAR T cells significantly controlled lymphoma cell growth, we observed that 3 weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells that were resistant to CD19 CAR T cell administration started to grow.

Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio

Retrieved on: 
Friday, January 20, 2023
B cell, Nanoparticle, Immunotherapy, Gene silencing, Survivin, DNA, Dendritic cell, Immunity, Cell, OTC, Dendrite, RNA, Exosome, SAN, Breast cancer, Science, Immune system, Vaccine

SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity.  The intellectual property provides additional means of stimulating specific elements of the immune system to selectively seek and destroy cancer cells without harming healthy tissue. 

Key Points: 
  • The intellectual property provides additional means of stimulating specific elements of the immune system to selectively seek and destroy cancer cells without harming healthy tissue.
  • Dendritic cells are the most potent immune cell capable of activating T cells.
  • The cancer marker survivin appears to be present on most of the major cancers but not on non-malignant tissues.
  • The Company has previously designed dendritic cells for treatment of breast cancer utlizing a process called gene silencing.

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunotherapy, ASCT, Diffuse large B-cell lymphoma, Partial, Hematological Cancer Research Investment and Education Act, IMV, Rutgers Cancer Institute of New Jersey, CD8, Endpoint security, Survivin, Pembrolizumab, CD4, ORR, SEDAR, Cancer, RWJBarnabas Health, TSX, DPX, Immune system, Cyclophosphamide, Bladder cancer, Degenerative disease, Patient, EDGAR, PD-L1, Pharmaceutical industry, Medical imaging, DLBCL

He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.

Key Points: 
  • He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.
  • Clinical activity in a highly refractory patient population may represent a path to registration in DLBCL.
  • The VITALIZE Phase 2B trial is a randomized, parallel group, Simon two-stage study designed to assess IMVs lead candidate, MVP-S, in combination with pembrolizumab with or without cyclophosphamide.
  • A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022.

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DLBCL, Toronto Stock Exchange, Immune system, EDGAR, Corporation, Immunotherapy, Survivin, CD8, IMV, Bladder cancer, CD4, TSX, SEDAR, DPX, Hematological Cancer Research Investment and Education Act, Vaccine

IMV Inc. (the Corporation or IMV) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.

Key Points: 
  • IMV Inc. (the Corporation or IMV) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.
  • The consolidation has taken effect on December 7, 2022, and the Corporations common shares commence trading on the Toronto Stock Exchange and on the Nasdaq Capital Market (Nasdaq) under the name IMV Inc. on a post-consolidation basis at the opening of markets today.
  • The consolidation is primarily intended to bring the Corporation into compliance with the minimum required closing bid price for continued listing on Nasdaq of US$1.00 per share.
  • IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Corporations immune-educating platform, DPX.

MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology

Retrieved on: 
Thursday, December 15, 2022
Journal of Clinical Oncology, Beth Israel Deaconess Medical Center, Science in newly industrialized countries, Phase, Recurrence, Dana–Farber Cancer Institute, Oncology, Overlook Medical Center, MD, Baptist Health, Immunotherapy, American Journal of Clinical Oncology, Fred Hutchinson Cancer Research Center, Doctor of Philosophy, Diagnosis, Cleveland Clinic, UCSF Medical Center, Progression-free survival, Patient, JCO, Roswell Park Comprehensive Cancer Center, Survivin, NYU Langone Health, Hospital, Survival rate, Baptist Health South Florida, Disease, Phases of clinical research, MOS, Cancer, Texas Oncology, Massachusetts General Hospital, Survival, Manuscript, Journal, Multimedia, IIA, GBM, MBA, Pharmaceutical industry, Medical imaging, Medical device, Glioblastoma

SurVaxM was developed to bring a paradigm shift to a field with few advancements in recent years.

Key Points: 
  • SurVaxM was developed to bring a paradigm shift to a field with few advancements in recent years.
  • MimiVax announces positive Phase 2A SurVaxM data in GBM, 2yr survival rate of 51%, published in JCO
    This multi-center, open label, single arm, phase IIa trial in adult patients with nGBM was approved by the institutional review boards at each of the participating hospitals [NCT02455557].
  • Of 63 patients enrolled, 60 (95.2%) remained progression-free 6 months after diagnosis to successfully reach the study primary endpoint.
  • "These promising results seen in the Phase IIa study compare favorably to the historical contemporary outcomes seen in glioblastoma.

IMV Shareholders Approve Reverse Stock Split at 88%

Retrieved on: 
Wednesday, December 7, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, DLBCL, Immune system, EDGAR, Corporation, Immunotherapy, Letter, Survivin, Indian stock exchange, CD8, IMV, Bladder cancer, CD4, SEDAR, DPX, Security (finance)

As a result of the reverse stock split, every 10 Common Shares issued and outstanding will be automatically reclassified into one new Common Share.

Key Points: 
  • As a result of the reverse stock split, every 10 Common Shares issued and outstanding will be automatically reclassified into one new Common Share.
  • The reverse stock split will not modify any rights or preferences of the Common Shares.
  • The Common Shares issued pursuant to the reverse stock split will remain fully paid and non-assessable.
  • Computershare Investor Services Inc. (Computershare), IMVs transfer agent, is acting as the exchange agent for the reverse stock split.